DePuy Synthes and CGBIO Enter Exclusive Distribution Agreement for NOVOSIS Bone Graft Substitute

Global leader in orthopaedic technologies and solutions, DePuy Synthes has formed an exclusive distribution agreement with the biotechnology company CGBIO, focused on regenerative medicine, for NOVOSIS, an advanced bone graft substitute using growth factors, to develop the product and prepare it for commercialisation. The agreement covers a spectrum of DePuy Synthes orthopaedic product lines, such as spine, craniomaxillofacial (CMF), and trauma applications.

Advancing Innovation in Bone Regeneration

NOVOSIS is an innovative bone graft material consisting of a bone graft substitute aimed to tackle issues with existing bone graft materials and provide better clinical results. An investigational device exemption (IDE) study of this product in spine procedures is ongoing, with enrollment continuing in the United States for an evaluation of the product's effectiveness and safety.  

Namal Nawana, Worldwide President of DePuy Synthes, stated, “NOVOSIS has the potential to meaningfully advance orthopaedic care as a transformative treatment option for patients. This partnership allows for leveraging their individual strengths and enables us to further develop differentiated technologies to address our identified unmet needs and support patient care.

According to Precedence Research, the Bone Grafts and Substitutes Market size was calculated at USD 3.38 billion in 2025 and is predicted to increase from USD 3.57 billion in 2026 to approximately USD  5.99 billion by 2035, expanding at a CAGR of 5.89% from 2026 to 2035, driven by the growing prevalence of musculoskeletal disorders and the rising demand for more innovative solutions in bone grafting.

Industry Impact and Outlook

DePuy Synthes' partnership with CGBIO underlines the orthopaedic sector with its new solutions in tissue regeneration. As there has been a push towards evolving to newer methods instead of the standard bone grafting approach, growth-factor-based bone graft substitutes have taken centre stage of interest with their potential to enhance bone fixation and improve treatment outcomes. 

Approval of NOVOSIS may aid in DePuy Synthes bone grafts and substitutes, expand access to the next generation of renewable treatment modalities to certain markets around the world, and provide a wedge for battling competition.